Acceptance, availability and feasibility of RTS, S/AS01 malaria vaccine: A review of literature

Abstract

Malaria remains the most serious infectious disease and is one of the leading causes of death among children in malaria endemic areas. The development of malaria vaccines has been underway since 1960s. Significant progress in the development of vaccine has been made in the last decade. On 6 October 2021, World Health Organization recommended widespread use of the RTS, S/AS01 malaria vaccine. The level of acceptance of RTS, S/AS01 malaria vaccine is relatively low in middle-income countries. This might be because of lack of information regarding vaccine implementation in such countries. The proper and efficient execution of the malaria vaccination program necessitates careful consideration of each community's socio-cultural setting. The most prominent RTS, S/AS01 vaccine trial was conducted from 2009 to 2011 in which eleven sites in seven African countries participated. Results of the trial, published in 2015, provided a promising advance in the development of a malaria vaccine for African children. As of 2019, large-scale pilot studies of the vaccine have been conducted in Ghana, Kenya, and Malawi, involving several hundreds of thousands of infants. The RTS, S/AS01 vaccine shows modest efficacy against malaria and has a feasible mode of administration. Although there is increased risk of meningitis, cerebral malaria, pneumonia, anemia, febrile convulsions and gastroenteritis, the vaccine still has a feasible mode of administration and high cost effectiveness and can be easily implemented in resource-limited settings.

Keywords

RTS, S/AS01 / Malaria / Plasmodium / Vaccine

References

[1] Saleh JA, Yusuph H, Zailani SB, Aji B. Malaria vaccine: The pros and cons. Niger J Med 2010; 19(1):8-13. doi: 10.4314/njm.v19i1.52464.

[2] Ayanful-Torgby R, Quashie NB, Boampong JN, Williamson KC, Amoah LE. Seasonal variations in Plasmodium falciparum parasite prevalence assessed by varying diagnostic tests in asymptomatic children in southern Ghana. PLoS One 2018; 13(6):e0199172.

[3] The Lancet Regional Health-Southeast Asia. 2030-Countdown to malaria elimination in India and Southeast Asia. [Online]. Available from:https://www.sciencedirect.com/science/article/pii/S2772368222000439?via%3Dihub. [Accessed on 17 April 2023].

[4] William B. The world malaria report 2015: Prospects for malaria elimination. Africa Health 2016; 38:14-16.

[5] Amador R, Patarroyo ME. Malaria vaccines. J Clin Immunol 1996; 16(4):183-189. doi: 10.1007/BF01541223.

[6] Schwartz L, Brown GV, Genton B, Moorthy VS. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012; 11:11. doi: 10.1186/1475-2875-11-11.

[7] Wagnew Y, Hagos T, Weldegerima B, Debie A. Willingness to pay for childhood malaria vaccine among caregivers of under-five children in northwest Ethiopia. Clinicoecon Outcomes Res 2021; 13:165-174. doi: 10.2147/CEOR.S299050.

[8] McCoy KD, Weldon CT, Ansumana R, Lamin JM, Stenger DA, Ryan SJ, et al. Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone. Malar J 2021; 20(1):183. doi: 10.1186/s12936-021-03723-0.

[9] Dickert N, Sugarman J. Ethical goals of community consultation in research. Am J Public Health 2005; 95(7):1123-1127. doi: 10.2105/AJPH.2004.058933.

[10] Angwenyi V, Kamuya D, Mwachiro D, Kalama B, Marsh V, Njuguna P, et al. Complex realities: Community engagement for a paediatric randomized controlled malaria vaccine trial in Kilifi, Kenya. Trials 2014; 15:65. doi: 10.1186/1745-6215-15-65.

[11] Ojakaa DI, Jarvis JD, Matilu MI, Thiam S. Acceptance of a malaria vaccine by caregivers of sick children in Kenya. Malar J 2014; 13:172. doi: 10.1186/1475-2875-13-172.

[12] Rahim S, Ahmad Z, Abdul-Ghafar J. The polio vaccination story of Pakistan. Vaccine 2022; 40(3):397-402. doi: 10.1016/j.vaccine.2021.11.095.

[13] Asmare G. Willingness to accept malaria vaccine among caregivers of under-5 children in Southwest Ethiopia: A community based cross-sectional study. Malar J 2022; 21(1):146. doi: 10.1186/s12936-022-04164-z.

[14] Mtenga S, Kimweri A, Romore I, Ali A, Exavery A, Sicuri E, et al. Stakeholders' opinions and questions regarding the anticipated malaria vaccine in Tanzania. Malar J 2016; 15:189. doi: 10.1186/s12936-016-1209-6.

[15] Maduka D, Adaobi I, Henrietta U. Acceptance of malaria vaccine by a rural community in Nigeria. Nigerian J Med 2018; 27(3):199.

[16] Ojakaa DI, Jarvis JD, Matilu MI, Thiam S. Acceptance of a malaria vaccine by caregivers of sick children in Kenya. Malar J 2014; 13:172. doi: 10.1186/1475-2875-13-172.

[17] Mose A, Wasie A, Shitu S, Haile K, Timerga A, Melis T, et al. Determinants of COVID-19 vaccine acceptance in Ethiopia: A systematic review and meta-analysis. PLoS One 2022; 17(6):e0269273. doi: 10.1371/journal.pone.0269273.

[18] Johns Hopkins Center for Communication Programs. Vaccine acceptance. 2021. [Online]. Available from:https://ccp.jhu.edu/kap-covid/vaccine-acceptance. [Accessed on 15 April 2023].

[19] Uzochukwu IC, Eleje GU, Nwankwo CH, Chukwuma GO, Uzuke CA, Uzochukwu CE, et al. COVID-19 vaccine hesitancy among staff and students in a Nigerian tertiary educational institution. Ther Adv Infect Dis 2021; 8:20499361211054923. doi: 10.1177/20499361211054923.

[20] Orangi S, Pinchoff J, Mwanga D, Abuya T, Hamaluba M, Warimwe G, et al. Assessing the level and determinants of COVID-19 vaccine confidence in Kenya. Vaccines (Basel) 2021; 9(8):936. doi: 10.3390/vaccines9080936.

[21] Bingham A, Gaspar F, Lancaster K, Conjera J, Collymore Y, Ba-Nguz A. Community perceptions of malaria and vaccines in two districts of Mozambique. Malar J 2012; 11:394. doi: 10.1186/1475-2875-11-394.

[22] Ojakaa DI, Ofware P, Machira YW, Yamo E, Collymore Y, Ba-Nguz A, et al. Community perceptions of malaria and vaccines in the South Coast and Busia regions of Kenya. Malar J 2011; 10:147. doi: 10.1186/1475-2875-10-147.

[23] Afolabi MO, Adetifa JU, Imoukhuede EB, Viebig NK, Kampmann B, Bojang K. Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in the Gambia: Frontline challenges in study design and implementation. Am J Trop Med Hyg 2014; 90(5):908-914. doi: 10.4269/ajtmh.13-0615.

[24] Dimala CA, Kika BT, Kadia BM, Blencowe H. Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review. PLoS One 2018; 13(12):e0209744. doi: 10.1371/journal.pone.0209744.

[25] Romore I, Ali AM, Semali I, Mshinda H, Tanner M, Abdulla S. Assessment of parental perception of malaria vaccine in Tanzania. Malar J 2015; 14:355. https://doi.org/10.1186/s12936-015-0889-7.

[26] World Health Organization. Countries-Malaria vaccine. [Online]. Available from:https://www.who.int/initiatives/malaria-vaccine-implementation-programme/countries. [Accessed on 26 August 2022].

[27] Centers for Disease Control and Prevention. Malaria-Malaria worldwide-How can malaria cases and deaths be reduced?-Vaccines. [Online]. Available from:https://www.cdc.gov/malaria/malaria_worldwide/reduction/vaccine.html. [Accessed on 26 August 2022].

[28] Centers for Disease Control and Prevention. Malaria. [Online]. Available from:https://www.cdc.gov/malaria/features/world_malaria_report_2009.html. [Accessed on 26 August 2022].

[29] World Health Organization. Malaria vaccine: WHO position paper, January 2016-Recommendations. Vaccine 2018; 36(25):3576-3577. doi: 10.1016/j.vaccine.2016.10.047.

[30] Laurens MB. RTS, S/AS01 vaccine (Mosquirix™): An overview. Hum Vaccin Immunother 2020; 16(3):480-489. https://doi.org/10.1080/21645515.2019.1669415.

[31] Asante KP, Ansong D, Kaali S, Adjei S, Lievens M, Nana Badu L, et al. Immunogenicity and safety of the RTS, S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial. Vaccine 2020; 38(18):3411-3421. doi: https://doi.org/10.1016/j.vaccine.2020.03.014.

[32] Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low- and middle-income countries, 2011-20. Health Aff (Millwood) 2016; 35(2):199-207.

[33] Pecenka C, Parashar U, Tate JE, Khan JAM, Groman D, Chacko S, et al. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh. Vaccine 2017; 35:3982-3987.

[34] Sarker AR, Sultana M. Cost-effective analysis of childhood malaria vaccination in endemic hotspots of Bangladesh. PLoS One 2020; 15(5):e0233902. doi: 10.1371/journal.pone.0233902.

[35] Fortpied J, Collignon S, Moniotte N, Renaud F, Bayat B, Lemoine D. The thermostability of the RTS, S/AS01 malaria vaccine can be increased by co-lyophilizing RTS, S and AS01. Malar J 2020; 19(1):202. doi: https://doi.org/10.1186/s12936-020-03253-1.

[36] Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med 2015; 373:2025-2037.

[37] Shehzad A, Parveen S, Qureshi M, Subhan F, Lee YS. Decursin and decursinol angelate: Molecular mechanism and therapeutic potential in inflammatory diseases. Inflamm Res 2018; 67:209-218. doi: 10.1007/s00011-017-1114-7.

[38] Nadeem AY, Shehzad A, Islam SU, Al-Suhaimi EA, Lee YS. Mosquirix™ RTS, S/AS01 vaccine development, immunogenicity, and efficacy. Vaccines 2022; 10(5):713. doi: https://doi.org/10.3390/vaccines10050713.

[39] Gosling R, von Seidlein L. The future of the RTS, S/AS01 malaria vaccine: An alternative development plan. PLoS Med 2016; 13(4):e1001994. doi: https://doi.org/10.1371/journal.pmed.1001994.

[40] RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet (London, England) 2015; 386(9988):31-45. doi: https://doi.org/10.1016/S0140-6736(15)60721-8.

[41] Gessner BD, Wraith DC, Finn A. CNS infection safety signal of RTS, S/AS01 and possible association with rabies vaccine. Lancet (London, England) 2016; 387(10026):1376. doi: https://doi.org/10.1016/S0140-6736(16)30081-2.

[42] Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS, S malaria vaccine and increased mortality in girls. mBio 2016; 7(2):e00514-e00516. doi: https://doi.org/10.1128/mBio.00514-16.

[43] Vekemans J, Marsh K, Greenwood B, Leach A, Kabore W, Soulanoudjingar S, et al. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: Case definition, standardization of data collection and patient care. Malar J 2011; 10:221. doi: 10.1186/1475-2875-10-221.